Medicamen Biotech has informed that the details of securities dematerialized / rematerialized during the quarter and half year ended on September 30, 2022, as required under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 have been furnished by its Registrar and Share Transfer Agent to all the Stock Exchanges, where the shares of the Company are listed (copy enclosed). The company has confirmed and certified that: The securities comprised in the said certificates(s) have been listed on the stock exchanges or exchanges were the earlier issued securities were listed and the certificates have been mutilated and cancelled after due verification and the name of the depository has been substituted in its records as the registered owner within 30 days of its receipt.
The above information is a part of company’s filings submitted to BSE.
